PMC8262189_01
Radiographic response to treatment. Computed tomography (CT) scans at initial diagnosis (A), seven months after taking alectinib for treatment (B), 17 months after taking alectinib for treatment (C), and two months after taking ceritinib for treatment (D), before the second chemotherapy cycle (E), before the 5th chemotherapy cycle (F).
pore-27-637745-g001.jpg
PMC8262189_01_pore-27-637745-g001.jpg
F1
Chest computed tomography (CT) showed a mass (about 42 x 55 mm) in his left lower lobe (Figure 1A) accompanied by the liver, scapula, and right frontal lobe metastases. On March 25th, 2019, we performed the chest CT on the patient to reexamine the tumor condition and found it almost disappeared (Figure 1B). On January 10th, 2020, a chest CT reexamination showed soft tissue density display in the left hilum (Figure 1C). On May 19th, 2020, the chest CT scan identified tumors in his left hilum (Figure 1D) and lower left lung, and the tumors blocked the left main bronchus. Combined with the CT results (Figure 1E&F), the patient's condition was assessed as stable disease.
Pathology with Hematoxylin-eosin (HE) stained and immunohistochemistry (IHC) results of the patient (x20 magnification). The baseline adenocarcinoma (ADC) HE result (A), ADC sample IHC analysis shows TTF-1:positive (B), p40:negative (C), ALK (clone D5F3):positive (D) and PD-L1 (clone SP263):TPS of 80% (E); the transformed squamous cell carcinoma (SCC) HE result (F), SCC sample IHC analysis shows TTF-1:negative (G), p40:positive (H), ALK (clone D5F3)-positive (I) and PD-L1 (clone SP263):TPS of 85% (J).
pore-27-637745-g002.jpg
PMC8262189_01_pore-27-637745-g002.jpg
F2
TPS of 80% and 85%, as determined with the SP263 assay (Figure 2 E&J). The patient began to receive abusartan combined with carboplatin chemotherapy on September 9th, 2020, and had completed five cycles of chemotherapy as of December 31st.
EML4-ALK fusion in the present case visualized using the Integrative Genomics Viewer (IGV). Diagrammatic sketch of EML4-ALK fusion result (A). The IGV display of EML4-ALK fusion in an adenocarcinoma specimen of EML4-ALK fusion results (B). The IGV display of EML4-ALK fusion in a squamous cell carcinoma specimen of EML4-ALK fusion results (C).
pore-27-637745-g003.jpg
PMC8262189_01_pore-27-637745-g003.jpg
F3